@article{0b6445bf93584a5f99abe860173cab8d,
title = "RASopathy mutations open new insights into the mechanism of BRAF activation",
abstract = "Spencer-Smith et al. (2022)1 investigate multiple functions of the BRAF cysteine-rich domain (CRD), finding distinct classes of RASopathy-associated BRAF mutations and unique features among RAF paralogs that may contribute to the spectrum of mutations observed in disease.",
author = "Dar, {Arvin C.} and Brady, {Donita C.}",
note = "Funding Information: We thank the following sources for funding: NIH (GM124749 and CA280833 to D.C.B. and CA227636, CA258736, CA256480, and R56 AG066712 to A.C.D.), Ludwig Cancer Research Princeton Branch to D.C.B. and the Mark Foundation for Cancer Research and Alex's Lemonade Stand Foundation for Childhood Cancer to A.C.D. D.C.B. holds ownership in Merlon Inc. and Elaeis Therapeutics, is an inventor on the patent application 20,150,017,261 (entitled “Methods of treating and preventing cancer by disrupting the binding of copper in the MAP kinase pathway”), and is a member of the Molecular Cell Advisory Board. A.C.D. is a founder, shareholder, advisory board member, and consultant to Nested Therapeutics. Funding Information: We thank the following sources for funding: NIH ( GM124749 and CA280833 to D.C.B. and CA227636 , CA258736 , CA256480 , and R56 AG066712 to A.C.D.), Ludwig Cancer Research Princeton Branch to D.C.B., and the Mark Foundation for Cancer Research and Alex{\textquoteright}s Lemonade Stand Foundation for Childhood Cancer to A.C.D. Publisher Copyright: {\textcopyright} 2022",
year = "2022",
month = nov,
day = "17",
doi = "10.1016/j.molcel.2022.10.034",
language = "English",
volume = "82",
pages = "4192--4193",
journal = "Molecular Cell",
issn = "1097-2765",
publisher = "Cell Press",
number = "22",
}